Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

The Defense Health Agency Aurora, on behalf of the TRICARE Management Activity, has issued solicitation HT9402-26-Q-9203 to establish an integrated pharmacy benefits program for the Military Health System. In accordance with 10 U.S.C. § 1074g and 32 CFR Section 199.21, the Department of War Pharmacy and Therapeutics (P&T) Committee evaluates pharmaceutical agents based on clinical and cost effectiveness. This process determines placement on the Uniform Formulary and classifies agents as generic, formulary, Basic Core Formulary, Extended Core Formulary, or non-formulary. The government intends to award Uniform Formulary Blanket Purchase Agreements (UF BPA) and Uniform Formulary Additional Discount Program (UF ADP) agreements based on these formulary decisions.

The scope of this solicitation involves Pharmaceutical Preparation Manufacturing under NAICS code 325412 and PSC 6505 for Drugs and Biologicals. For the May 2026 P&T Committee meeting, the agency will review several newly approved drugs, including Arynta, Atmeksi, Avtozma, Desmoda, Foundayo, Icotyde, Kygevvi, Lerochol, Loargys, and Yuviwel. These drugs cover various therapeutic classes such as ADHD agents, skeletal muscle relaxants, endocrine agents, and metabolic agents. Performance is centered in San Antonio, Texas, and the notice includes 14 attachments providing price lists, frequently asked questions, and formulary placement guidelines.

Quotations and clinical responses must be submitted by the response deadline of April 27, 2026. A pre-quotation teleconference is scheduled for April 15, 2026, to provide further details as outlined in the solicitation instructions. Specific responses to clinical questions must be submitted via email to the designated point of contact, Stephanie Erpelding. The solicitation and its associated price appendices serve as the formal request for industry quotes prior to the scheduled committee review.